Results 101 to 110 of about 3,026 (154)

Correction to: Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study. [PDF]

J Crohns Colitis
europepmc   +1 more source

<i>Clostridioides difficile</i> Infection in Special Populations: Focus on Inflammatory Bowel Disease-A Narrative Review from Pathogenesis to Management. [PDF]

Biomedicines
Seguiti C, Tettoni E, Pezzuto E, Gerardi V, Quadarella A, Cesaro P, Colombini P.   +6 more
europepmc   +1 more source

Subgroup Analyses in Randomized Trials of Clostridioides difficile-Associated Disease: Recurring Challenges With Analyzing Recurrence. [PDF]

Clin Infect Dis
Strength RE, Immel SR, Drobish IC, Powers JH.   +3 more
europepmc   +1 more source

Bezlotoxumab for the prevention of recurrent <i>Clostridioides difficile</i> infection for patients with cancer. [PDF]

Ann Gastroenterol
Peña JA, Mazhuvanchery CB, Santos MJMN, Naz S, Cruz CC, Wali S, Varatharajalu K, Okhuysen PC, Vuong NN, Wang Y.   +9 more
europepmc   +1 more source

Fidaxomicin Reduces Collagen Expression in Intestinal Fibroblasts Via Platelet-Derived Growth Factor Receptor Beta and Glycogen Synthase Kinase-3 Beta Inhibition. [PDF]

Gastroenterology
Irwin S, van Daelen M, Almaraz I, Park R, Nelson B, Mahurkar-Joshi S, Rieder F, Shih DQ, Ho W, Limketkai B, Koon HW.   +10 more
europepmc   +1 more source

A Tale of Two Infections: A Rare Synchronous Infection of Herpes Simplex Virus Oesophagitis and Clostridium difficile in an Immunocompetent Host. [PDF]

Cureus
Lama S, Moe AT, Akinloye A, Tun KS, Karedath J.   +4 more
europepmc   +1 more source